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Pneumocystis jirovecii is an uncultivable fungal pathogen responsible for Pneumocystis
pneumonia (PCP) in immunocompromised patients, the physiopathology of which is
only partially understood. The diversity of the Pneumocystis strains associated with
acute infection has mainly been studied by Sanger sequencing techniques precluding
any identification of rare genetic events (<20% frequency). We used next-generation
sequencing to detect minority variants causing infection, and analyzed the complexity
of the genomes of infection-causing P. jirovecii. Ultra-deep pyrosequencing (UDPS)
of PCR amplicons of two nuclear target region [internal transcribed spacer 2 (ITS2)
and dihydrofolate reductase (DHFR)] and one mitochondrial DNA target region [the
mitochondrial ribosomal RNA large subunit gene (mtLSU)] was performed on 31 samples
from 25 patients. UDPS revealed that almost all patients (n = 23/25, 92%) were infected
with mixtures of strains. An analysis of repeated samples from six patients showed that
the proportion of each variant change significantly (by up to 30%) over time on treatment
in three of these patients. A comparison of mitochondrial and nuclear UDPS data revealed
heteroplasmy in P. jirovecii. The recognition site for the homing endonuclease I-SceI
was recovered from the mtLSU gene, whereas its two conserved motifs of the enzyme
were not. This suggests that heteroplasmy may result from recombination induced
by unidentified homing endonucleases. This study sheds new light on the biology of
P. jirovecii during infection. PCP results from infection not with a single microorganism, but
with a complex mixture of different genotypes, the proportions of which change over time
due to intricate selection and reinfection mechanisms that may differ between patients,
treatments, and predisposing diseases.
Keywords: ultra-deep pyrosequencing, Pneumocystis jirovecii, mixed infection, mitochondria, heteroplasmy,
recombination
INTRODUCTION
Pneumocystis jirovecii is an ascomycete fungus that specifically infects humans (Cushion,
2010; Gigliotti and Wright, 2012) and causes Pneumocystis pneumonia (PCP), mostly
in immunocompromised patients, including HIV-positive, solid organ transplant, and
cancer/hematology patients, but also in adults and children with various other underlying
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conditions (Pagano et al., 2002; Roblot et al., 2003; Catherinot
et al., 2010; Wissmann et al., 2010; Reid et al., 2011; Mori and
Sugimoto, 2012; Tasaka and Tokuda, 2012). P. jirovecii thrives
at the surface of alveolar pneumocytes, but is unable to grow on
standard artificial media. It can, however, be amplified in vitro
in an air-liquid interface culture system (Schildgen et al., 2014).
These characteristics have made it difficult to study its genetic
diversity, complexity, and evolution in humans. In addition, the
genome sequence of P. jirovecii is only recently publicly available
(Cissé et al., 2012; Cushion and Keely, 2013).
Since the 1990s, specific tools have been used to study the
genetic diversity of P. jirovecii. In addition to cloning and
sequencing (Tsolaki et al., 1996), single-strand conformation
polymorphism (Hauser et al., 2001; Hauser, 2004), single-
nucleotide extension assays (Esteves et al., 2011; Alanio et al.,
2015), multi-locus sequencing typing (MLST) (Maitte et al.,
2013), and short tandem repeat (STR)-based genotypingmethods
(Parobek et al., 2014; Gits-Muselli et al., 2015) have shown that
mixtures of genotypes, differing in at nuclear or mitochondrial
loci, are present during active infection. It has been estimated
that up to 70% of patients with PCP harbor multiple genotypes,
as assessed in various populations and by diverse techniques
targeting nuclear or mitochondrial genes (Hauser et al., 2001;
Parobek et al., 2014; Gits-Muselli et al., 2015). Studies based
on Sanger sequencing have also reported the presence of mixed
P. jirovecii sequences, but in a lower proportion of patients
(about 30%) due to the well-known poor sensitivity of the
Sanger method for detecting minority alleles (Angulo et al.,
2010).
The genetic diversity of P. jirovecii has mostly been
investigated in epidemiological studies, in which little attention
was paid to the differences between nuclear and mitochondrial
markers. The mitochondrial ribosomal RNA large subunit
gene is currently used as a PCR target for PCP diagnosis
(Meliani et al., 2003; Alanio et al., 2011, 2016; Botterel et al.,
2012) and for typing based on MLST (Maitte et al., 2013).
However, the nuclear and mitochondrial genomes can behave
differently. Indeed, mitochondrial DNA can undergo more
recombination events and acquire more mutations over time
than nuclear DNA (Fritsch et al., 2014). The mitochondrial
genome of P. jirovecii has recently been sequenced and
compared to those of other Pneumocystis species (Ma et al.,
2013). Although the mitochondrial genome of Pneumocystis
carinii and Pneumocystis murina are thought to be linear,
that of P. jirovecii appears to consist of a double-stranded
circular mitochondrial DNA (mtDNA) molecule (Ma et al.,
2013) that is autonomously replicated, transcribed, and mostly
encodes proteins involved in mitochondrial respiration (Chen
and Butow, 2005). In fungi, the mitochondrial genome
mostly displays uniparental inheritance (Basse, 2010) and is
autonomously replicated and transcribed (Chatre and Ricchetti,
2014).
We therefore investigated the diversity of P. jirovecii
sequences, using ultra-deep pyrosequencing (UDPS) to
detect minority variants and to compare the dynamics of
the mitochondrial and nuclear genomes in the context of
infection.
MATERIALS AND METHODS
Ethics Statement
Saint-Louis Hospital, Paris, France, is a 650-bed tertiary
university hospital with major clinical activities in hematology,
renal transplantation, and oncology. This study was a
non-interventional study with no change in the usual procedures.
Biological material and clinical data were obtained only for
standard diagnostic following physicians’ prescriptions with no
specific sampling. According to the French Health Public Law
(CSP Art L1121-1.1), such protocol does not require approval
of an ethics committee and is exempted from specific informed
consent application.
Patients and Samples
We studied a collection of 31 respiratory samples from 25
patients with PCP treated at our university hospital (Saint
Louis Hospital, Paris, France). Patients and samples were
selected randomly from a collection of sputum or BAL fluids
from patients with PCP and a high load of fungal DNA
(Cq < 30, Alanio et al., 2011). Diagnosis was based on
clinical (pulmonary infection in immunocompromised patients),
radiological (interstitial pneumonia, ground glass opacities),
and biological findings (ascus observed on immunofluorescence
analyses of smears of respiratory material). DNA was extracted
as previously described (Alanio et al., 2011). Our real-time
quantitative PCR assay confirmed the high fungal load in all
samples (>1900 EqTr/ml) (Alanio et al., 2011). The median
age of the patients was 50 years (range: 1–80 years), and the
sex ratio (M/F) was 5.25. The patients were HIV-positive (n
= 12, 48%), had hematological malignancies (n = 6, 24%), were
kidney transplant recipients (n = 4, 16%) or had another cause
of immunodeficiency (n = 3, 12%). Two samples were collected
from each of six patients (12 samples) with a median interval
between samples of 7.5 (1–18) days. All samples had already been
genotype with a recently described short-tandem repeat (STR)
genotyping assay (Gits-Muselli et al., 2015). The six STR markers
used were evenly distributed in the nuclear genome, as shown
by alignment with the P. murina genome sequence (Gits-Muselli
et al., 2015). The limit of detection for mixed STR markers was
shown experimentally to be 2% (Gits-Muselli et al., 2015).
Selection of Target Genes and Amplicons
We were able to analyze amplicons of up to 320 bp in
length in specific assays. The 5.8S-ITS2-28S (n = 120), DHFR
(n = 60), and mtLSU (n = 52) sequence hits collected
from Nucleotide Blast (https://blast.ncbi.nlm.nih.gov/Blast.cgi?
PAGE_TYPE=BlastSearch) were aligned, using Geneious 7.1
(Biomatters Ltd., New Zealand). We selected primers (Table S2)
binding to conserved regions and allowing the amplification
of sequences of about 300 bp in length, to maximize the
number of polymorphic positions detected (Figures S1A–
S3A). The primers were designed with Primer3web v 4.0.0
(http://primer3.ut.ee).
Specific Gene Amplification by UDPS
Each PCR primer consisted of a specific adaptor (5′-
CGTATCGCCTCCCTCGCGCCATCAG-3′ for forward primers
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and 5′CTATGCGCCTTGCCAGCCCGCTCAG-3′ for reverse
primers), a sample-specific multiplex identifier (MID) sequence,
and a specific amplification sequence for PCR (Table S2).
We obtained three amplicons for each sample. Each amplicon
(22.5 µl) was diluted with an equal volume of water and
purified with AMPure beads (72 µl), before quantification with
a Qubit R© ds DNA HS Assay kit (Life Technologies) on a Qubit
3.0 instrument. For each gene, the PCR amplicons from 16
samples were pooled in equimolar concentrations and used to
prepare an equimolar mixture of 107 molecules. This pool was
subjected to clonal amplification on capture beads by emulsion
PCR. In total, 500,000 beads enriched in DNA were deposited
into the wells of a PicoTiter plate device and subjected to
pyrosequencing in both directions with the GS Junior system
(Roche). After a 10-h run, total reads were analyzed with GS
amplicon variant analyzer (AVA) software (Roche), filtered and
assigned, by demultiplexing, to the correct patient sample on the
basis of MID correspondence.
Analysis of UDPS Data
AVA software (Roche) also aligned the generated sequence
reads with the chosen reference sequence (JQ365725 for 5.8S-
ITS2-28S, AF090368 for DHFR, JX499143 for mtLSU) and
identified the proportion of polymorphism for each variable
position in the sequences amplified. Insertions and deletions
were not considered. Only already known SNPs were taken into
account and haplotypes representing >0.5% of the sequences
were selected for further analysis, to prevent the introduction of
false polymorphic regions due to PCR errors (Brodin et al., 2013).
Each individual combination of SNPs was selected and called
haplotypes.
Reproducibility was determined by testing the same sample in
two runs. The proportion of each of the variants sequenced varied
by no more than 2%.
In all analyses, we studied one sample per patient (n= 25): the
first sample collected. Specific analyses of repeated samples were
performed separately.
Screening for the Presence of a Homing
Endonuclease
We screened for the presence of conserved I-SceI motifs
(GIGLILGDA and LAYWFMDDG) or motifs derived from
this enzyme from Taphrina deformans (IVGLMLGDGY and
LAVWISDDG) and for the recognition site of this enzyme
(AAGTTACGCTAGGGATAACGGGGTAATATAGC) in the
mitochondrial genome of P. jirovecii (JX499143), with Geneious
v8.0 (Biomatters Ltd.).
Graphs and Statistical Analysis
Sequence analysis graphs were generated with Geneious v8.0
(Biomatters Ltd.). Hierarchical clustering was performed by
Pearson’s correlation analysis and average linkage clustering,
with MeV v4.6.1 open-source genomic analysis software (The
TM4 Development Group) obtained from www.tm4.org (Saeed
et al., 2006). All graphs were plotted and statistical analyses (t-
tests, One-way ANOVA, chi-square) were performed with Prism
software v.6.0 (Graphpad).
RESULTS
UDPS Detected Numerous Variant
Sequences
We used UDPS to analyze the diversity of three genetic
sequences in 31 respiratory samples from 25 patients. We
investigated two nuclear DNA target regions [partial 5.8S,
internal transcribed spacer 2 and partial 28S gene (ITS2),
GenBank accession n◦JQ365725] and the [partial dihydrofolate
reductase gene (DHFR), GenBank accession n◦AF090368] and
one mitochondrial DNA target region [partial mitochondrial
ribosomal RNA large subunit gene (mtLSU), GenBank accession
n◦JX499143] (Figures S1A–S3A). The ITS2 locus was selected
because this target DNA has already been used for genotyping
P. jirovecii samples (de Boer et al., 2007; Le Gal et al., 2012)
and is known to be present as a single copy in the P. jirovecii
genome (Nahimana et al., 2000; Cissé et al., 2012; Cushion
and Keely, 2013). The dihydrofolate reductase gene (DHFR,
target gene of trimethoprim (diaminopyrimidine), one of the
components of cotrimoxazole) was also selected because it
was a single-copy gene and because mutations of this gene
have already been described and potentially associated with the
failure of cotrimoxazole prophylaxis (Nahimana et al., 2004;
Queener et al., 2013). The mtLSU locus is the DNA target
most widely used for diagnosis, it is known to be single-
copy in the mitochondrial genome (Ma et al., 2013), with
the mitochondria and mitochondrial genome being replicated
several times within each organism. Two runs per gene were
performed by multiplexing. After filtering, sequences were
obtained and aligned with the corresponding reference sequence
(with a mean of 6552 ± 3525, 8107 ± 2625, 4022 ± 1892 reads
for ITS2, DHFR, and mtLSU, respectively).
Polymorphisms were observed at positions 135 (T135A),
230 (T230A), and 232 (G232A or G232C) of the 277 bp ITS2
amplicon, at positions 192 (T192C) and 218 (A218G) of the 300
bp DHFR amplicons, and at positions 84 (A84T or A84C) and
247 (C247T) of the 314-bpmtLSU amplicons (Figure 1,Table S1,
Figures S1B–S3B). We used these polymorphisms to determine
the haplotypes [combination of single nucleotide polymorphisms
(SNPs)] of the 31 samples. Overall, seven variants (type of
haplotypes) were found for ITS2 (TTG [WT], ATG, AAG, TAT,
ATC, TTA, AAA), three for DHFR (TA [WT], CA, and TG)
and six for mtLSU (AC [WT], TT, AT, CC, CT, TC) (Figure 1,
Figures S1B–S3B).
We avoided bias in the interpretation of diversity, by analyzing
the proportions of the variants in the 25 baseline samples, as
repeat samples were available for six of the 25 patients. Overall,
the number of different variants (Table 1, Figure 2) and the
proportion of each variant (Figure 3) in each sample differed.
Variation of the Number and Proportion of
Variants, Revealing Possible Heteroplasmy
The distribution of the number of variants observed differed
significantly between mtLSU, ITS2 and DHFR (Kruskal-Wallis,
p < 0.0001, Figure 2A, Figure S4A). Up to four, two and six
variants/sample were observed for ITS2, DHFR, and mtLSU,
respectively. No technical bias was observed, because there was
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FIGURE 1 | Variants of the three Pneumocystis jirovecii target DNA regions observed in our collection of samples by ultra-deep pyrosequencing
(UDPS). Analysis of all 31 samples led to the identification of seven variants for the internal transcribed spacer two region (ITS2), two for the partial dihydrofolate
reductase gene (DHFR), and six for the mitochondrial ribosomal RNA large subunit gene (mtLSU), with respect to reference sequences (GenBank Accession number:
JQ365725, AF090368, and JX499143, respectively). Of note, for ITS2, the numbering corresponds to the ITS2 region and not to that of the whole amplicon. For the
ITS2 target, three polymorphic bases at positions 66, 161, and 163 of the ITS2 region resulted in the observation of seven variants: TTG, TTA, ATA, AAA, AAG, ATG,
and ATC. For the DHFR gene, two polymorphic bases at positions 192 and 218 of the amplicon resulted in the observation of only three variants. For the mtLSU
target, two polymorphic bases at positions 84 and 247 of the amplicon resulted in the observation of six variants: AG (WT), TT, AT, CC, CT, and TC. Dots indicate
bases identical to the reference sequence. Polymorphic bases are shown in color. The size of the consensus base (sequence Logo) is proportional to the proportion of
sequences polymorphic at the corresponding position. WT, wild-type sequence corresponding to the reference sequence; MT, mutated sequence corresponding to
polymorphic variants.
no significant correlation (p > 0.05) between the number of
variants and fungal load (based on quantification cycle or Cq
value) or total number of reads sequenced (Figure S4B). Clusters
of samples based on the number of variants for the three targets
could be defined (Table 1, Figure 2B). These clusters were not
significantly associated with the patient’s background (p > 0.05).
The proportion of the total number of reads sequenced for
each target corresponding to each of the variants was determined
for each of the 25 samples (Figure 3). Samples were classified as
pure (single variant on UDPS analysis) or mixed (≥2 variants)
sequences. Pure sequences were observed in only 5/25 samples
for ITS2 (20%), 17/25 samples for DHFR (68%), and 2/25 (8%)
of samples for mtLSU (Table 1, Figure 3). Some of the samples
could be clustered on the basis of the proportions of variants, but
the pattern of clustering differed between target genes (Figure 4).
Based on the combined UDPS data for the two nuclear target
genes (ITS2, DHFR), pure sequences were observed in 5/25
(20%) patients (samples #090, 149, 175, 192, 252) (Figure 2). The
genotyping results obtained with the six STR nuclear markers
(Gits-Muselli et al., 2015) were consistent with purity (a single
allele detected for each of the six markers) for three of these five
samples (#090, 192, 252) (Table 1). Two of these five samples
(#090, 192) harbored a single mtLSU variant. The other three
(#252, 149, 175) had mixed mtLSU sequences, with three, six
and two mtLSU variants, respectively (Table 1). These results
(polymorphic mtLSU sequences with unique nuclear markers)
were suggestive of heteroplasmy.
Homing Endonuclease May Be Present in
Pneumocystis jirovecii
We searched for the presence of a homing endonuclease site
in the mtLSU sequence, because such heteroplasmy could have
been acquired through mtDNA recombination events initiated
by intron homing (Haugen et al., 2005). Analysis of the
complete mtLSU sequence (JX499143) revealed the presence of
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TABLE 1 | Number of variants observed and resulting classifications of each sample for the three DNA target regions analyzed using UDPS and the six
STR markers.
Sample N◦ Number of variants Nuclear genome
UDPS
Nuclear genome
UDPS + STR
Mitochondrial
genome
UDPS STR typing nuclear markers
Mitochodrial Nuclear
mtLSU ITS2 DHFR 022 108 138 189 278 279
Pj_SLS_024 6 2 2 1 1 2 2 1 1 Mixed Mixed both Mixed
Pj_SLS_240 6 2 2 1 1 1 2 1 3 Mixed Mixed both Mixed
Pj_SLS_250 6 2 2 2 1 1 3 1 1 Mixed Mixed both Mixed
Pj_SLS_256 6 2 2 1 1 3 3 2 2 Mixed Mixed both Mixed
Pj_SLS_272 5 3 2 2 1 2 3 1 1 Mixed Mixed both Mixed
Pj_SLS_045 4 2 1 1 2 2 2 1 1 Mixed Mixed both Mixed
Pj_SLS_317 4 4 1 1 1 2 2 1 1 Mixed Mixed both Mixed
Pj_SLS_070 3 4 1 1 1 2 2 1 2 Mixed Mixed both Mixed
Pj_SLS_235 3 2 1 1 1 1 2 1 1 Mixed Mixed both Mixed
Pj_SLS_253 3 3 1 1 1 2 2 1 1 Mixed Mixed both Mixed
Pj_SLS_030 2 2 2 1 1 1 2 1 1 Mixed Mixed both Mixed
Pj_SLS_181 2 3 2 1 2 1 1 1 1 Mixed Mixed both Mixed
Pj_SLS_189 2 3 1 1 1 3 1 1 1 Mixed Mixed both Mixed
Pj_SLS_209 2 3 1 1 1 2 1 1 3 Mixed Mixed both Mixed
Pj_SLS_060 2 3 1 1 1 1 1 1 1 Mixed Mixed UDPS Mixed
Pj_SLS_113 4 3 2 1 1 1 1 1 1 Mixed Mixed UDPS Mixed
Pj_SLS_178 2 3 1 1 1 1 1 1 1 Mixed Mixed UDPS Mixed
Pj_SLS_197 3 3 1 1 1 1 1 1 1 Mixed Mixed UDPS Mixed
Pj_SLS_223 2 3 1 1 1 1 1 1 1 Mixed Mixed UDPS Mixed
Pj_SLS_268 3 2 1 1 1 1 1 1 1 Mixed Mixed UDPS Mixed
Pj_SLS_149 6 1 1 1 2 1 1 1 1 Pure Mixed STR Heteroplasmy
Pj_SLS_175 2 1 1 1 1 1 2 1 1 Pure Mixed STR Heteroplasmy
Pj_SLS_252 3 1 1 1 1 1 1 1 1 Pure Pure Heteroplasmy
Pj_SLS_090 1 1 1 1 1 1 1 1 1 Pure Pure Pure
Pj_SLS_192 1 1 1 1 1 1 1 1 1 Pure Pure Pure
a recognition site 81.25% identical to that described for the
I-SceI of Saccharomyces cerevisiae (Dujon, 1980; Jacquier and
Dujon, 1985). Only six of the 32 nucleotides differed from those
present in the motif described for I-SceI (Figure 5) (Belfort and
Roberts, 1997). The two conserved motifs (GIGLILGDA and
LAYWFMDDG) of I-SceI were not found in the mtLSU DNA
sequence, even if we used the motifs present in T. deformans
(IVGLMLGDGY and LAVWISDDG), which, like Pneumocystis,
belongs to the Taphrinomycotina subphylum (Cissé et al., 2014;
Almeida et al., 2015).
Patient-Based Analysis of P. jirovecii
Diversity
The characteristics of the 25 patients are summarized in Table 2.
Sex ratio was 7.3 and median age was 54 years. The patients were
HIV-positive (n= 15), patients with hematological malignancies
(n = 7), renal transplant recipients (n = 4), and had other
causes of immunosuppression (n = 5). The country of birth was
recovered in 21 patients and was France (n = 14), Haiti (n = 2),
North Africa (n= 2), Romania (n= 1), Vietnam (n= 1), Comoro
Islands (n= 1). In total, no significant correlation (p > 0.05) was
found between the presence of the different variants for each gene
or for the combination of the three genes and the gender, the
age, the background, the country of birth of the patients and the
evolution at month 3.
For the six patients with repeated samples (median time
between the first and second samples: 7.5 days, range: 1–18 days),
the proportions of the variants varied by more than 2% (cutoff
for reproducibility) in all patients, and by more than 10% in
two patients (P14, P25) (Table 3). In addition to the differences
in the proportions of the variants present, some of the variants
were present in one sample, and absent from the other in five
patients (P2, P3, P14, P24, and P25), although the proportion of
this variant was below 2% when it was present in some cases (P2,
P3, P14, P24). Even for samples recovered only a few days apart
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FIGURE 2 | Distribution of the number of variants found in each sample for the mtLSU, ITS2, and DHFR DNA targets. Each of the 25 samples is
represented as an independent dot (A). The number of variants was significantly different between the three genes (one-way ANOVA, p < 0.0001), with mtLSU and
ITS having significantly more variants than DHFR. The bar represents the median for each target region. Each of the samples is represented by a line linking the
number of variants found for each of the three genes (B). Similar patterns in the distribution of the variants can be seen for our 25 samples.
(2 days for P2, and 1 day for P14), the proportions of the variants
varied by up to 24.9% between samples (ITS2 and TAT for P2,
ITS2 and TTG for P14) (Table 3). In P25, oneDHFR variant (CA)
accounted for 30.4% of the variants present 8 days after the first
sample was collected and cotrimoxazole treatment was initiated
(Table 3). Clustering on the basis of the proportion of variants for
the three targets revealed that the two samples from P2, P3, and
P18 clustered together, whereas those from P14, P24, and P25 did
not (Figure 4).
DISCUSSION
Our next-generation sequencing results indicate that
Pneumocystis infections are mostly mixed infections. UDPS
of nuclear gene targets revealed that 80% of the samples
harbored mixed sequences, and this proportion increased to
92% (23/25) when a mitochondrial DNA target was added to the
analysis.
Primary infection occurs early in life, with about 85%
of children displaying anti-Pneumocystis antibody-mediated
immune responses by the age of 18 months (Meuwissen
et al., 1977; Pifer et al., 1978) and the detection of fungal
DNA in non-invasive respiratory samples (Vargas et al., 2001).
Immunocompetent or immunosuppressed individuals act as a
reservoir for P. jirovecii, which infects immunocompromised
patients via airborne transmission (Gigliotti et al., 2003;
Chabé et al., 2004; Choukri et al., 2010), as demonstrated
by epidemiological studies of numerous PCP outbreaks in
a context of intrahospital transmission, particularly in renal
transplant units (de Boer et al., 2011). The high predominance
of mixed infection observed in our study may reflect continuous
exposure throughout life (Gigliotti and Wright, 2012), together
with the active multiplication of a subset of strains during
immunosuppression. Some strains may be less capable of
active multiplication than others in specific settings and in
a given patient. This does not exclude the possibility that
reactivation from dormancy contributes to the diversity observed
during infection, because differences have been observed in
the geographic distributions of P. jirovecii genotypes (Alanio
et al., 2015). From an epidemiologic standpoint, these findings
demonstrate that mitochondrial genes, including the mtLSU
gene in particular, should be used with caution for the MLST
genotyping of P. jirovecii because the mitochondrial and nuclear
genomes may evolve differently.
Different mechanisms are thought to be involved inmutations
of the mitochondrial genome. Mitochondrial DNA is subjected
to more rounds of replication than nuclear DNA, and this may
result in a higher frequency of point mutations. Mutations may
also accumulate more easily due to higher levels of exposure to
reactive oxygen species and, finally, the DNA repair machinery
of the mitochondria has been shown to be less efficient than
that of the nucleus (Song et al., 2005). Interestingly, five
samples harbored pure nuclear (ITS and DHFR) sequences but
mixed mitochondrial sequences, suggesting that heteroplasmy
had occurred. Of course, we cannot completely rule out
the possibility of polymorphism in other nuclear sequences.
However, the analysis of six additional nuclear markers by
STR typing (high level of discrimination and widespread
distribution within the P. jirovecii genome; Gits-Muselli et al.,
2015) was consistent with purity (unique genotype) for three
samples. Heteroplasmy has already been reported in fungi,
mostly for filamentous fungi (Barr et al., 2005). However,
heteroplasmy seems to be rare in most fungi, due to uniparental
mitochondrial transmission (Barr et al., 2005). In laboratory
conditions, heteroplasmy is controlled and used to study mtDNA
recombination (Basse, 2010). By contrast, heteroplasmy has
rarely been studied in natural populations. Mitochondrial gene
variation between isolates has been demonstrated by cloning in
arbuscular mycorrhizal fungi (Rhizophagus irregularis) (Beaudet
et al., 2015), with the identification of up to 20 variants per
isolate for various mitochondrial target regions, all different from
mtLSU. This aspect has been studied in natural populations
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FIGURE 3 | Proportion of each variant observed in 25 samples, by
UDPS, for the mtLSU, ITS2, and DHFR DNA targets. The proportion of
each variant after pyrosequencing analysis (AVA software, Roche) is depicted
for each target DNA region, ITS2, DHFR, mtLSU, and for the 25 baseline
samples. Each variant is represented by a different color and samples are
grouped to allow the visualization of clusters based on the proportion of the
variants (this grouping differs for the three targets). Pure samples (“p”) are
shown for each target. Pure sequences (proportion of 100%) were observed in
5/25 samples for ITS2 (20%), 17/25 samples for DHFR (68%), and 2/25
samples for mtLSU (8%). The number of times each variant was recovered
and the proportions of the variants differed between samples, with some
clusters observed. Based on the combined data for the two nuclear DNA
targets (ITS2, DHFR), pure sequences were observed in 5/25 (20%) samples
(samples 090, 149, 175, 192, 252). Two of these samples were also identified
as pure (“p”) for the mtLSU DNA target (samples 090 and 192), whereas the
other three samples harbored mixtures of sequences for mtLSU, consistent
with mitochondrial heteroplasmy (“h”). Variants accounting for <0.5% of all
sequences and variants with unknown polymorphisms were not considered in
this study.
of only two medically important fungi, Candida albicans
(Anderson et al., 2001) and Cryptococcus gattii (Xu et al.,
2009), to our knowledge. In both cases, the authors used PCR
followed by Sanger sequencing and strain culture, assuming
that the culture was clonal and therefore had only one nuclear
genome. As expected, given the greater sensitivity of UDPS, we
detected a higher degree of polymorphism within P. jirovecii
mtLSU. Moreover, we had to control for the uniqueness of
the nuclear genome in the absence of a simple culture system.
Heteroplasmy was, therefore, expected in UDPS with a 0.5%
cutoff value for variant selection. The uncultivable nature of
P. jirovecii complicates studies of this phenomenon and the
interpretation of its importance. However, recently developed
culture methods may facilitate studies of the dynamics of
FIGURE 4 | Heatmap of the proportions of the different variants in the
31 samples analyzed by UDPS, for the mtLSU, ITS2, and DHFR DNA
targets. The 31 samples were clustered by hierarchical clustering analysis
based on the proportions of the variants recovered. Samples from the six
patients from whom repeat samples were obtained are indicated by a colored
box (P14 in red, P2 in green, P24 in orange, P25 in black, and P3 in blue). The
clustering analysis showed that, for P2, P18, and P3, the proportion of variants
varied little between the two samples, which clustered together. By contrast,
for P14, P24, and P25, significant differences in the proportions of variants
were observed, leading to the two samples from the same patient being
assigned to different clusters. Gray indicates an absence of recovery, blue
indicates a low proportion (<10%) and yellow indicates a high proportion
(>70%), as indicated by the scale bar at the top of each heatmap.
heteroplasmy (Schildgen et al., 2014). However, homoplasmy
is widely described in various organisms and controlled by
genetic mechanisms (Christie et al., 2015). The observation of
heteroplasmy in P. jirovecii could be the consequence of the lack
of the control mechanisms that tend to decrease heteroplasmy
rates are not present in P. jirovecii, or their ineffectiveness during
the active phase of disease. P. jirovecii could also regularly or
occasionally inherit mitochondria from both parents. In addition,
a genetic phenomenon called intron homing responsible for
recombination in the mitochondrial genome could lead to
heteroplasmy.
Homing endonuclease genes (HEGs) are widespread in fungal
genomes and are generally located in self-splicing introns (Basse,
2010). A recognition site for the homing endonuclease I-SceI was
found in the S. cerevisiae mtLSU gene (Dujon, 1980; Jacquier
and Dujon, 1985). This suggests that heteroplasmy in P. jirovecii
may result from recombination due to the double-strand breaks
created by such enzymes in mitochondrial DNA. However, the
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classical LAGLIDADG (Belfort and Roberts, 1997) motif and the
conserved motifs GIGLILGDA and LAYWFMDDG (Chevalier
et al., 2005) were not detected in the mtLSU gene, even if the
mitochondrial homolog from T. deformans (the closest relative
FIGURE 5 | Alignment of the recognition site for the homing
endonuclease I-SceI with the corresponding region in the P. jirovecii
mtLSU gene. The I-SceI homing endonuclease has a specific recognition site
for double-strand DNA break and intron introduction. A putative recognition
site for this enzyme was identified between positions 14,635 and 14,666
(JX499143). Nucleotides identical to the consensus sequence are shown in
gray, whereas polymorphic positions are shown in color. Solid- and dotted-line
arrows indicate cleavages on the presented and complementary strands,
respectively. The triangle indicates the intron insertion site (adapted from
Belfort and Roberts, 1997).
of Pneumocystis; Cissé et al., 2013, 2014; Almeida et al., 2015)
was used as the reference (GenBank: CAUL01000001). This
suggests that theremay be as yet undiscovered homologs of I-SceI
endonucleases in P. jirovecii.
Several variants, including those of the mtLSU target, were
clearly present at the time of disease diagnosis, when fungal
load was high. The observed diversity may also be due to
mutations acquired during active growth of the fungus during
immunosuppression and in the days or weeks before diagnosis.
We cannot exclude the possibility of a peculiar variant having a
selective advantage over another variant, resulting in changes in
their relative proportions overtime. A stable final equilibrium in
the proportion of variants may be reached in some patients, but
not in others. Indeed, we observed variations in the proportions
of variants in analyses of results for the serial samples obtained
from some patients. This variation may also be due to differences
in the sampling method, because P. jirovecii isolates recovered
from BAL or sputum have already been shown to be different
from those recovered from lung tissue (Helweg-Larsen et al.,
2001). One patient (P25) with AIDS acquired a mutation of
the DHFR target DNA (T192C) in about 30% of all DHFR
sequences 8 days after the initiation of cotrimoxazole treatment
(Table S1). This mutation corresponds to a T1158C synonymous
substitution (called T312C in Nahimana et al., 2004) with no
effect on protein function and not reflecting the acquisition
TABLE 2 | Clinical characteristics of the 25 patients sampled in this study.
Patient N◦ Sex Age Country of birth Background CD4 count (/mm3) Prophylaxis Treatment Outcome at month 3
P1 M 32 Na HIV 48 No Cotrimoxazole Alive
P2 M 50 Haiti HIV 81 No Cotrimoxazole Alive
P3 M 10 Na Systemic lupus erythematosus na na na na
P4 M 47 Metropolitan France HIV 216 No Cotrimoxazole Alive
P5 F 20 Metropolitan France Lymphoma na Pentacarinat Atovaquone Alive
P6 M 65 Vietnam HIV 2 No Pentacarinat Alive
P7 M 45 North Africa Kidney SOT 170 No Cotrimoxazole Alive
P8 M 45 Metropolitan France HIV 2 No Cotrimoxazole Alive
P9 M 42 Metropolitan France Lymphoma na No Cotrimoxazole Alive
P10 M 48 Na HIV na na na na
P11 M 56 Metropolitan France Kidney SOT na No Cotrimoxazole Alive
P12 F 64 Metropolitan France Kidney SOT 59 No Cotrimoxazole Alive
P13 M 33 Metropolitan France HIV 12 No Cotrimoxazole Alive
P14 M 69 Comores Lymphoma 11 No Cotrimoxazole Death
P15 M 66 North Africa HIV 116 No Cotrimoxazole Alive
P16 M 54 Haiti Kidney SOT 268 No Cotrimoxazole na
P17 M 59 Metropolitan France HIV 20 No Cotrimoxazole Alive
P18 M 57 Na Lung cancer na No Cotrimoxazole Alive
P19 M 0.3 Metropolitan France Neonate na na na na
P20 M 50 Metropolitan France HIV 38 No Cotrimoxazole Alive
P21 M 81 Metropolitan France Lymphoma na No Cotrimoxazole Alive
P22 M 56 Metropolitan France Lymphoma 256 No Cotrimoxazole Alive
P23 F 57 Metropolitan France HSCT and Lymphoma 9 Atovacone Cotrimoxazole Death
P24 M 62 Metropolitan France HIV 56 No Cotrimoxazole Alive
P25 M 60 Roumania HIV 10 No Cotrimoxazole Alive
na: not available.
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of a resistance mutation. The other coding regions of this
gene have not been studied and may contain other mutations.
However, the observed variant accounted for only 30% of all
variants, and complete recovery with no clinical resistance to
cotrimoxazole was observed. The detection of this variant only
8 days after the introduction of cotrimoxazole treatment could
suggest acquisition of a mutation during proliferation in the
presence of the drug or selection and proliferation of this under
treatment pressure.
Our study provides additional evidence for the complex
natural history of P. jirovecii infections, for which the three
Henle-Koch’s postulates long used to evaluate the causal
relationship between an infectious agent and a clinically defined
disease can’t be applied (Evans, 1976; Falkow, 1988). We show
that these infections are mostly associated with mixtures of
strains/genotypes that were probably acquired over the course
of the patient’s life. This finding is consistent with the current
view of the natural history of these infections: reservoir in
individual with various backgrounds (immunocompetent infants
and adults or individuals with chronic pulmonary diseases
such as chronic obstructive pulmonary disease or with relative
immunosuppression such as children and pregnant women;
Peterson and Cushion, 2005) and direct airborne transmission
(Cushion, 2010; Gigliotti and Wright, 2012). However, we still
know little about the subjects carrying P. jirovecii but not
developing active infection (Hauser et al., 2000; Morris and
Norris, 2012), as the low fungal load in respiratory samples
from these individuals precludes such analyses, particularly for
single-copy nuclear DNA targets.
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Figure S1 | Alignment of ITS2 sequences recovered from GenBank (n
= 120) (A) and of the amplicons recovered from our patients, with the
polymorphic bases highlighted (B).
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Figure S2 | Alignment of DHFR sequences recovered from GenBank
(n = 60) (A) and of the amplicons recovered from our patients, with the
polymorphic bases highlighted (B).
Figure S3 | Alignment of mtLSU sequences recovered from GenBank (n =
52) (A) and of the amplicons recovered from our patients, with the
polymorphic bases highlighted (B).
Figure S4 | Distribution of the number of variants found in each sample for
mtLSU, ITS2, and DHFR DNA targets, as determined by UDPS and with six
nuclear STR markers (A). Distribution of fungal load (left panel) and the number
of reads for each patient (one dot per patient, n = 31), classified by the maximum
number of variants recovered per sample (1–4 for ITS, 1–2 for DHFR, and 1–6 for
mtLSU) (B).
Table S1 | Correspondence between the position of the observed
polymorphic bases described in our samples and their position in the
reference sequence, with the corresponding amino acid
substitution.
Table S2 | Primers and PCR conditions used.
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